Open Access

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

  • Authors:
    • Zi-Nan Li
    • Ying Luo
  • View Affiliations

  • Published online on: November 9, 2022     https://doi.org/10.3892/or.2022.8443
  • Article Number: 6
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Heat shock protein 90 (HSP90) is a vital chaperone protein, regulating signaling pathways and correcting misfolded proteins in cancer cells by interacting with oncogenic client proteins and co‑chaperones. The inhibition of HSP90 chaperone machinery has been demonstrated as a potential approach with which to inhibit tumor survival, proliferation, invasion and migration. Numerous HSP90 inhibitors have been reported and have exhibited value as cancer‑targeted therapies by interrupting the ATPase activity of HSP90, thus suppressing the oncogenic pathways in cancer cells. These inhibitors have been classified into three categories: i) N‑terminal domain (NTD) inhibitors; ii) C‑terminal domain (CTD) inhibitors; and iii) isoform‑selective inhibitors. However, none of these HSP90 inhibitors are used as clinical treatments. The major limiting factors can be summarized into drug resistance, dose‑limiting toxicity and poor pharmacokinetic profiles. Novel HSP90‑targeted compounds are constantly being discovered and tested for their antitumor efficacy in preclinical and clinical trials, highlighting the prospect of the use of HSP90 inhibitors as cancer‑targeted therapies. Additionally, improved antitumor effects have been observed when HSP90 inhibitors are used in combination with chemotherapy, targeted agents, or immunotherapy. In the present review, the effects of HSP90 inhibitors on the management of the cancer process are discussed and previous and novel HSP90‑based therapeutic strategies in cancer treatment are summarized. Furthermore, prospective HSP90‑targeting candidates are proposed for their future evaluation as cancer treatments.
View Figures
View References

Related Articles

Journal Cover

January-2023
Volume 49 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Z and Li Z: HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncol Rep 49: 6, 2023
APA
Li, Z., & Li, Z. (2023). HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review). Oncology Reports, 49, 6. https://doi.org/10.3892/or.2022.8443
MLA
Li, Z., Luo, Y."HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)". Oncology Reports 49.1 (2023): 6.
Chicago
Li, Z., Luo, Y."HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)". Oncology Reports 49, no. 1 (2023): 6. https://doi.org/10.3892/or.2022.8443